TcLand Expression is a privately held molecular diagnostics company. TcLand Expression’s investors range from family funds to venture capitalist & corporate investors. They bring to TcLand Expression extensive strategic, financial, scientific and practical expertise.
Original shareholders include the founders of TcLand Expression and researchers from ITERT in Nantes, France, one of Europe’s leading kidney transplantation centers.
The main investors since the December 2007 Series A financing round are:
Investor Relations Contact
TcLand Expression SA
Halle 13, Bio-Ouest Ile de Nantes
21 Rue de la Noue Bras de Fer
|T +33 2 40 35 89 99
F +33 2 40 35 67 20
|Auriga Partners is an independent venture capital firm based in Paris, France. It invests in innovative, high-potential ventures in information & communication technology and life science at the seed or early development stage in Europe, North America and Israel. Auriga Partners manages three funds totaling over €330 million. As well as investing the necessary capital, Auriga Partners also provides its portfolio companies with its know-how in developing and solidifying executive teams, structuring companies, broadening their networks and forming strategic & corporate alliances.
For further information, please visit www.auriga-partners.com
|“QUEST FOR GROWTH” is a Pan-European investment company that invests in technology-based growth companies throughout Europe and in a broad range of industrial sectors, such as information technology, semiconductors, telecommunications, software, electronics, biotechnology, medical devices, health care and new materials. QUEST FOR GROWTH invests in both quoted and unquoted companies. QUEST FOR GROWTH is traded on the continuous segment at Euronext Brussels. The “QUEST FOR GROWTH” fund is managed by Quest Management NV, an independent asset manager in Belgium.|
|Beviguen is a private holding company which makes equity investments in the following sectors: healthcare, environment & climate, non-food retail and information & communication technology.|
|Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery & formulation and regulatory affairs.
Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2006.
For more information on Debiopharm Group, please visit: www.debiopharm.com
|One of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2006 revenues of $3.2 billion.
With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and diagnostic testing. Genzyme’s commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease and other areas of unmet medical need.